ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis) Research Package

Jay Achar; Vineed Bhatia; Amy Bloom; Jonathon Campbell; Sarabjit Chadha; Masuc Dara; Andrei Dadu; Dennis Falzon; Katherine Fielding; Jennifer Furin; Agnes Gebhard; Christine Ho; Ernesto Jaramillo; Igne Koppelaar; Jeremy Hill; Maria Idrissova; Viktoriya Livchits; Knut Lönnroth; Tiziana Masini; Fuad Mirzayev; Carole Mitnick; Ignacio Monedero; Fukushi Morishita; Asif Muhammad; YaDiul Mukadi; Mariam Otami Del Barrio; Alberto Piubello; Laura Rosu; Anna Scardigli; Kseniia Serdiuk; Bertie Squire; Edine Tiemersma; Ewan Tomeny; Mohammed Yassin; Askar Yedilbayev; Sabine Verkuijl; Eliud Wandwalo; Fraser Wares; Matteo Zignol

ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis) Research Package

Jay Achar
, Vineed Bhatia
, Amy Bloom
, Jonathon Campbell
, Sarabjit Chadha
, Masuc Dara
, Andrei Dadu
, Dennis Falzon
, Katherine Fielding
, Jennifer Furin
, Agnes Gebhard
, Christine Ho
, Ernesto Jaramillo
, Igne Koppelaar
, Jeremy Hill
, Maria Idrissova
, Viktoriya Livchits
, Knut Lönnroth
, Tiziana Masini
, Fuad Mirzayev

Carole Mitnick, Ignacio Monedero, Fukushi Morishita, Asif Muhammad, YaDiul Mukadi, Mariam Otami Del Barrio, Alberto Piubello, Laura Rosu, Anna Scardigli, Kseniia Serdiuk, Bertie Squire, Edine Tiemersma, Ewan Tomeny, Mohammed Yassin, Askar Yedilbayev, Sabine Verkuijl, Eliud Wandwalo, Fraser Wares, Matteo Zignol

Research output: Working paper

Abstract

TDR in close collaboration with the Global TB Programme at WHO and technical partners the WHO Global TB Programme is leading the development of ShORRT (Short, all-Oral Regimens For Rifampicin-resistant Tuberculosis), an operational research package to assess the effectiveness, safety, feasibility, acceptability, cost and impact (including on health-related quality of life) of the use of all-oral shorter drug regimens for adults and children with MDR/RR-TB.

Original language	English
Publisher	World Health Organization
Publication status	Published - 20 Feb 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

ShORRT-Generic-protocol-v2Feb2020Final published version, 1.19 MBLicence: CC BY

Cite this

Achar, J., Bhatia, V., Bloom, A., Campbell, J., Chadha, S., Dara, M., Dadu, A., Falzon, D., Fielding, K., Furin, J., Gebhard, A., Ho, C., Jaramillo, E., Koppelaar, I., Hill, J., Idrissova, M., Livchits, V., Lönnroth, K., Masini, T., ... Zignol, M. (2020). ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis) Research Package. World Health Organization.

@techreport{3747fb3119ad4f64802969b993956cbf,

title = "ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis) Research Package",

abstract = "TDR in close collaboration with the Global TB Programme at WHO and technical partners the WHO Global TB Programme is leading the development of ShORRT (Short, all-Oral Regimens For Rifampicin-resistant Tuberculosis), an operational research package to assess the effectiveness, safety, feasibility, acceptability, cost and impact (including on health-related quality of life) of the use of all-oral shorter drug regimens for adults and children with MDR/RR-TB.",

author = "Jay Achar and Vineed Bhatia and Amy Bloom and Jonathon Campbell and Sarabjit Chadha and Masuc Dara and Andrei Dadu and Dennis Falzon and Katherine Fielding and Jennifer Furin and Agnes Gebhard and Christine Ho and Ernesto Jaramillo and Igne Koppelaar and Jeremy Hill and Maria Idrissova and Viktoriya Livchits and Knut L{\"o}nnroth and Tiziana Masini and Fuad Mirzayev and Carole Mitnick and Ignacio Monedero and Fukushi Morishita and Asif Muhammad and YaDiul Mukadi and \{Otami Del Barrio\}, Mariam and Alberto Piubello and Laura Rosu and Anna Scardigli and Kseniia Serdiuk and Bertie Squire and Edine Tiemersma and Ewan Tomeny and Mohammed Yassin and Askar Yedilbayev and Sabine Verkuijl and Eliud Wandwalo and Fraser Wares and Matteo Zignol",

year = "2020",

month = feb,

day = "20",

language = "English",

publisher = "World Health Organization",

address = "Switzerland",

type = "WorkingPaper",

institution = "World Health Organization",

}

Achar, J, Bhatia, V, Bloom, A, Campbell, J, Chadha, S, Dara, M, Dadu, A, Falzon, D, Fielding, K, Furin, J, Gebhard, A, Ho, C, Jaramillo, E, Koppelaar, I, Hill, J, Idrissova, M, Livchits, V, Lönnroth, K, Masini, T, Mirzayev, F, Mitnick, C, Monedero, I, Morishita, F, Muhammad, A, Mukadi, Y, Otami Del Barrio, M, Piubello, A, Rosu, L, Scardigli, A, Serdiuk, K, Squire, B, Tiemersma, E, Tomeny, E, Yassin, M, Yedilbayev, A, Verkuijl, S, Wandwalo, E, Wares, F & Zignol, M 2020 'ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis) Research Package' World Health Organization.

TY - UNPB

T1 - ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis) Research Package

AU - Achar, Jay

AU - Bhatia, Vineed

AU - Bloom, Amy

AU - Campbell, Jonathon

AU - Chadha, Sarabjit

AU - Dara, Masuc

AU - Dadu, Andrei

AU - Falzon, Dennis

AU - Fielding, Katherine

AU - Furin, Jennifer

AU - Gebhard, Agnes

AU - Ho, Christine

AU - Jaramillo, Ernesto

AU - Koppelaar, Igne

AU - Hill, Jeremy

AU - Idrissova, Maria

AU - Livchits, Viktoriya

AU - Lönnroth, Knut

AU - Masini, Tiziana

AU - Mirzayev, Fuad

AU - Mitnick, Carole

AU - Monedero, Ignacio

AU - Morishita, Fukushi

AU - Muhammad, Asif

AU - Mukadi, YaDiul

AU - Otami Del Barrio, Mariam

AU - Piubello, Alberto

AU - Rosu, Laura

AU - Scardigli, Anna

AU - Serdiuk, Kseniia

AU - Squire, Bertie

AU - Tiemersma, Edine

AU - Tomeny, Ewan

AU - Yassin, Mohammed

AU - Yedilbayev, Askar

AU - Verkuijl, Sabine

AU - Wandwalo, Eliud

AU - Wares, Fraser

AU - Zignol, Matteo

PY - 2020/2/20

Y1 - 2020/2/20

N2 - TDR in close collaboration with the Global TB Programme at WHO and technical partners the WHO Global TB Programme is leading the development of ShORRT (Short, all-Oral Regimens For Rifampicin-resistant Tuberculosis), an operational research package to assess the effectiveness, safety, feasibility, acceptability, cost and impact (including on health-related quality of life) of the use of all-oral shorter drug regimens for adults and children with MDR/RR-TB.

AB - TDR in close collaboration with the Global TB Programme at WHO and technical partners the WHO Global TB Programme is leading the development of ShORRT (Short, all-Oral Regimens For Rifampicin-resistant Tuberculosis), an operational research package to assess the effectiveness, safety, feasibility, acceptability, cost and impact (including on health-related quality of life) of the use of all-oral shorter drug regimens for adults and children with MDR/RR-TB.

M3 - Working paper

BT - ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis) Research Package

PB - World Health Organization

ER -

ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis) Research Package

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this